Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CMO Noah Rosenberg bought 4,200 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was acquired at an average cost of $4.91 per share, for a total transaction of $20,622.00. Following the completion of the acquisition, the chief marketing officer directly owned 6,557 shares in the company, valued at approximately $32,194.87. This trade represents a 178.19% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Verrica Pharmaceuticals Stock Performance

VRCA stock traded down $0.21 on Tuesday, hitting $4.68. The company’s stock had a trading volume of 46,708 shares, compared to its average volume of 92,498. The stock has a market cap of $80.40 million, a price-to-earnings ratio of -2.80 and a beta of 1.49. The firm has a 50 day moving average of $5.68 and a two-hundred day moving average of $5.93. The company has a current ratio of 1.45, a quick ratio of 1.33 and a debt-to-equity ratio of 0.18. Verrica Pharmaceuticals Inc. has a 1 year low of $3.28 and a 1 year high of $9.82.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on VRCA. Wall Street Zen cut shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. HC Wainwright began coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Zacks Research raised Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $14.50.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of large investors have recently bought and sold shares of VRCA. AQR Capital Management LLC raised its position in Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after buying an additional 44,275 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at about $28,000. Invesco Ltd. increased its stake in shares of Verrica Pharmaceuticals by 64.8% during the first quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock worth $33,000 after acquiring an additional 29,256 shares during the period. Bridgeway Capital Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the third quarter worth about $52,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Verrica Pharmaceuticals by 23.3% during the first quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company’s stock worth $61,000 after acquiring an additional 26,308 shares during the period. Hedge funds and other institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.